Cell Therapies names new CEO
28 April, 2014 by Dylan Bushell-EmblingCell Therapies has selected Dr Tim Oldham to become its new CEO to help drive the company's South-East Asian growth strategy.
Phosphagenics completes enrolment in acne trial
24 April, 2014 by Dylan Bushell-EmblingPhosphagenics has completed enrolment for a phase II trial of an acne treatment candidate that uses its TPM transdermal drug delivery technology.
Export study reveals barriers for Australian companies
24 April, 2014The most comprehensive export survey of its type, Australia's International Business Survey, was conducted to understand and highlight the major issues facing exporters.
QRxPharma faces third FDA knockback for Moxduo
24 April, 2014 by Dylan Bushell-EmblingAn FDA advisory committee has recommended against approving QRxPharma's (ASX:QRX) third NDA for dual-opioid pain relief product Moxduo IR.
Analytica launches $3m capital raising
23 April, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) is raising up to $3m through a placement and entitlement offer to help accelerate its marketing efforts for female urinary incontinence treatment device PeriCoach.
ResMed launches two new AirFit masks
22 April, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has added a new nasal mask and a full-face mask to its AirFit line of sleep-disordered breathing therapy devices.
AusBiotech to submit to Senate's 'Australian innovation system' inquiry
22 April, 2014AusBiotech is preparing a submission following the Senate's referral of an inquiry into Australia's innovation system to the Senate Economics References Committee for inquiry and report.
Drawbridge anaesthetic beats propofol during trial
17 April, 2014 by Dylan Bushell-EmblingDrawbridge Pharmaceuticals announced that anaesthesia candidate Phaxan outperformed the SOC propofol during the first in-human trial comparing the two drugs.
TGA's low value turnover exemption scheme under review
17 April, 2014The Therapeutic Goods Administration (TGA) has announced a review of the low value turnover exemption scheme (LVT scheme), which exempts cost recovery fees on products with low turnover.
Queensland Government to inject $1m into MRCF
17 April, 2014 by Dylan Bushell-EmblingThe Queensland Government will kick another $1m into the Medical Research Commercialisation Fund (MRCF), a VC fund jointly supported by the federal, Qld, Vic, NSW and WA governments.
Nexvet raises $33.6m in financing round
17 April, 2014 by Dylan Bushell-EmblingNexvet Biopharma will put the proceeds of a $33.6m Series B financing round to funding key clinical trials for its lead products, as well as expanding its development pipeline and US presence.
ResMed gets Red Dots for respiratory products
15 April, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has secured Red Dot designation for a nasal pillow mask and a soon-to-be-launched life support ventilator at this year's awards.
pSivida partner gets new PDUFA date
15 April, 2014 by Dylan Bushell-EmblingThe US FDA has set a PDUFA date of 26 September for pSivida (ASX:PVA) partner Alimera Sciences' fourth new drug application for diabetic macular edema treatment Iluvien.
Program announced for 2014 global agri-biotech conference in Canada
15 April, 2014This year's Agricultural Biotechnology International Conference (ABIC) has launched its program. Registrations are now open for the event, to be held from 5-8 October in Saskatoon, Saskatchewan, Canada.
Reforming Employee Share Schemes for the good of start-up innovation
14 April, 2014 by Dr Anna LavelleAn effective employee share scheme would enable start-up companies to attract and retain the quality employees they need to become established successful ventures.
